Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland.
Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
J Cereb Blood Flow Metab. 2020 Jun;40(6):1167-1171. doi: 10.1177/0271678X20906815. Epub 2020 Feb 16.
Stroke remains a major cause of serious disability due to the brain's limited capacity to regenerate. Current treatments focus on acute recanalization of the occluded blood vessels; however, currently there are no approved therapy options to regenerate neural circuits and reduce stroke-related disability. To promote recovery, therapeutic angiogenesis has been proposed as a promising target. Although restoration of blood vessels providing oxygen and nutrients to the peri-infarct regions may be beneficial, newly generated capillaries may also carry pathophysiological risk factors that need to be considered. One major concern are adverse effects including edema formation and haemorrhagic transformation due to the comprised endothelial barrier function during vascular remodelling. This brief opinion article will discuss the challenges and the newest advancements of angiogenesis as a therapeutic strategy for ischemic stroke.
由于大脑再生能力有限，中风仍然是导致严重残疾的主要原因。目前的治疗方法侧重于闭塞血管的急性再通；然而，目前尚无经批准的治疗方案来再生神经回路并减少与中风相关的残疾。为了促进恢复，治疗性血管生成已被提议作为一个有前途的靶点。尽管恢复为梗塞周边区域提供氧气和营养的血管可能是有益的，但新生成的毛细血管也可能携带需要考虑的病理生理危险因素。一个主要关注点是由于血管重塑过程中内皮屏障功能受损，导致水肿形成和出血转化等不良反应。这篇简短的观点文章将讨论血管生成作为治疗缺血性中风的策略所面临的挑战和最新进展。
